Dupilumab (anti–IL-4Rα) showed 30–34% reduction in exacerbations, improved FEV1, and QoL in eosinophilic, CB-phenotype COPD patients in the BOREAS and NOTUS trials [94,95]. Here, IL4R is linked to chronic obstructive pulmonary disease.